{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:00:32Z","timestamp":1780966832470,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Japan Science and Technology Agency FOREST Program","award":["JPMJFR205J"],"award-info":[{"award-number":["JPMJFR205J"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03658-7","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:54:57Z","timestamp":1775537697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evaluation of adherence to single-inhaler triple therapy in chronic obstructive pulmonary disease: the LIFE Study"],"prefix":"10.1186","volume":"27","author":[{"given":"Hiroaki","family":"Ogata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotsugu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"3658_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 report. https:\/\/goldcopd.org\/2025-gold-report.\u00a0Accessed 14 Dec 2025."},{"key":"3658_CR2","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death.\u00a0Accessed 19 Dec 2025."},{"key":"3658_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e56\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"3658_CR4","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399:2227\u201342.","journal-title":"Lancet"},{"key":"3658_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2017.06.007","volume":"129","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117\u201323.","journal-title":"Respir Med"},{"key":"3658_CR6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ M\u00e4kel\u00e4","year":"2013","unstructured":"M\u00e4kel\u00e4 MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481\u201390.","journal-title":"Respir Med"},{"key":"3658_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435\u201341.","journal-title":"Respir Med"},{"key":"3658_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.rmed.2013.08.044","volume":"108","author":"JFM Van Boven","year":"2014","unstructured":"Van Boven JFM, Chavannes NH, Van Der Molen T, Rutten-van M\u00f6lken MPMH, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108:103\u201313.","journal-title":"Respir Med"},{"key":"3658_CR9","doi-asserted-by":"publisher","first-page":"e001964","DOI":"10.1136\/bmjresp-2023-001964","volume":"11","author":"D Vauterin","year":"2024","unstructured":"Vauterin D, Van Vaerenbergh F, Grymonprez M, Vanoverschelde A, Lahousse L. Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis. BMJ Open Respir Res. 2024;11:e001964.","journal-title":"BMJ Open Respir Res"},{"key":"3658_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thx.2009.113662","volume":"64","author":"J Vestbo","year":"2009","unstructured":"Vestbo J, Anderson JA, Calverley PMA, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939\u201343.","journal-title":"Thorax"},{"key":"3658_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.rmed.2007.05.001","volume":"101","author":"G Tamura","year":"2007","unstructured":"Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895\u2013902.","journal-title":"Respir Med"},{"key":"3658_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1164\/rccm.201604-0733OC","volume":"195","author":"I Sulaiman","year":"2017","unstructured":"Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333\u201343.","journal-title":"Am J Respir Crit Care Med"},{"key":"3658_CR13","unstructured":"AstraZeneca plc. AstraZeneca annual report and form 20-F information 2024. https:\/\/www.astrazeneca.com\/content\/astraz\/investor-relations\/annual-reports\/annual-report-2024.html.\u00a0Accessed 23 Dec 2025."},{"key":"3658_CR14","unstructured":"GlaxoSmithKline plc. Annual report 2024. https:\/\/www.gsk.com\/en-gb\/investors\/financial-reports\/annual-report-2024.\u00a0Accessed 23 Dec 2025."},{"key":"3658_CR15","doi-asserted-by":"publisher","first-page":"1642470","DOI":"10.3389\/fphar.2025.1642470","volume":"16","author":"MA Gonz\u00e1lez-Gonz\u00e1lez","year":"2025","unstructured":"Gonz\u00e1lez-Gonz\u00e1lez MA, Pedrosa-Naud\u00edn MA, Fern\u00e1ndez-L\u00e1zaro D, Planelles ID, \u00c1lvarez FJ, Guti\u00e9rrez-Abej\u00f3n E. Single- versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes. Front Pharmacol. 2025;16:1642470.","journal-title":"Front Pharmacol"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/COPD.S424497","volume":"19","author":"M Bogart","year":"2024","unstructured":"Bogart M, Bengtson L, Johnson M, Bunner SH, Gronroos NN, DiRocco K. Outcomes following initiation of triple therapy with fluticasone furoate\/umeclidinium\/vilanterol versus multiple-inhaler triple therapy among Medicare Advantage with part D beneficiaries and those commercially enrolled for health care insurance in the United States. Int J Chron Obstruct Pulmon Dis. 2024;19:97\u2013110.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3658_CR17","doi-asserted-by":"publisher","first-page":"e080864","DOI":"10.1136\/bmjopen-2023-080864","volume":"14","author":"S Jok\u0161ait\u0117","year":"2024","unstructured":"Jok\u0161ait\u0117 S, Wood R, Ismaila A, Camidge L, Mizukami A, Czira A, et al. Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study. BMJ Open. 2024;14:e080864.","journal-title":"BMJ Open"},{"key":"3658_CR18","doi-asserted-by":"publisher","first-page":"175346662412634","DOI":"10.1177\/17534666241263439","volume":"18","author":"P Steiropoulos","year":"2024","unstructured":"Steiropoulos P, Georgatou N, Krommidas G, Bartziokas K, Korkontzelou A, Katerelos P, et al. Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study. Ther Adv Respir Dis. 2024;18:17534666241263439.","journal-title":"Ther Adv Respir Dis"},{"key":"3658_CR19","doi-asserted-by":"publisher","first-page":"106807","DOI":"10.1016\/j.rmed.2022.106807","volume":"197","author":"D Mannino","year":"2022","unstructured":"Mannino D, Bogart M, Wu B, Germain G, Lalibert\u00e9 F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: a real-world study. Respir Med. 2022;197:106807.","journal-title":"Respir Med"},{"key":"3658_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12325-024-03055-w","volume":"42","author":"C Young","year":"2025","unstructured":"Young C, Lee LY, DiRocco KK, Germain G, Klimek J, Lalibert\u00e9 F, et al. Adherence and persistence with single-inhaler triple therapy among patients with COPD using commercial and Medicare Advantage US health plan claims data. Adv Ther. 2025;42:830\u201348.","journal-title":"Adv Ther"},{"key":"3658_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2188\/jea.JE20210513","volume":"33","author":"H Fukuda","year":"2023","unstructured":"Fukuda H, Ishiguro C, Ono R, Kiyohara K. The Longevity Improvement & Fair Evidence (LIFE) Study: overview of the study design and baseline participant profile. J Epidemiol. 2023;33:428\u201337.","journal-title":"J Epidemiol"},{"key":"3658_CR22","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303\u201310.","journal-title":"Curr Med Res Opin"},{"key":"3658_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41440-020-0440-2","volume":"43","author":"S Nishimura","year":"2020","unstructured":"Nishimura S, Kumamaru H, Shoji S, Sawano M, Kohsaka S, Miyata H. Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan. Hypertens Res. 2020;43:705\u201314.","journal-title":"Hypertens Res"},{"key":"3658_CR24","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.2147\/COPD.S370540","volume":"17","author":"DM Halpin","year":"2022","unstructured":"Halpin DM, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis. 2022;17:2417\u201329.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3658_CR25","first-page":"198","volume":"27","author":"LGS Bengtson","year":"2021","unstructured":"Bengtson LGS, Bancroft T, Schilling C, Buikema AR, Stanford RH. Development and validation of a drug adherence index for COPD. J Manag Care Spec Pharm. 2021;27:198\u2013209.","journal-title":"J Manag Care Spec Pharm"},{"key":"3658_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/COPD.S184653","volume":"14","author":"M Bogart","year":"2019","unstructured":"Bogart M, Stanford RH, Lalibert\u00e9 F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3658_CR27","first-page":"178","volume":"53","author":"H Kimura","year":"2010","unstructured":"Kimura H, Toga H, Yamaya M, Mishima M, Nukiwa T, Kudo S. Current situations and issues in respiratory medicine in Japan. Jpn Med Assoc J. 2010;53:178\u201384.","journal-title":"Jpn Med Assoc J"},{"key":"3658_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/HJH.0000000000003661","volume":"42","author":"K Sagara","year":"2024","unstructured":"Sagara K, Goto K, Maeda M, Murata F, Fukuda H. Medication adherence and associated factors in newly diagnosed hypertensive patients in Japan: the LIFE study. J Hypertens. 2024;42:718\u201326.","journal-title":"J Hypertens"},{"key":"3658_CR29","unstructured":"Local Government in Japan. 2020 (2022 revised edition). https:\/\/www.clair.or.jp\/j\/forum\/pub\/docs\/jichi2022-en.pdf.\u00a0Accessed 14 Dec 2025."},{"key":"3658_CR30","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijmedinf.2013.07.004","volume":"82","author":"Y Yoshida","year":"2013","unstructured":"Yoshida Y, Imai T, Ohe K. The trends in EMR and CPOE adoption in Japan under the national strategy. Int J Med Inf. 2013;82:1004\u201311.","journal-title":"Int J Med Inf"},{"key":"3658_CR31","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.21037\/jtd-20-2360","volume":"13","author":"EM Jansen","year":"2021","unstructured":"Jansen EM, Van De Hei SJ, Dierick BJH, Kerstjens HAM, Kocks JWH, Van Boven JFM. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. J Thorac Dis. 2021;13:3846\u201364.","journal-title":"J Thorac Dis"},{"key":"3658_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/jcpt.13126","volume":"45","author":"X Jia","year":"2020","unstructured":"Jia X, Zhou S, Luo D, Zhao X, Zhou Y, Cui Y. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systematic review and meta\u2010analysis. J Clin Pharm Ther. 2020;45:904\u201317.","journal-title":"J Clin Pharm Ther"},{"key":"3658_CR33","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bcp.12242","volume":"77","author":"E Tommelein","year":"2014","unstructured":"Tommelein E, Mehuys E, Van Hees T, Adriaens E, Bortel LV, Christiaens T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 2014;77:756\u201366.","journal-title":"Br J Clin Pharmacol"},{"key":"3658_CR34","doi-asserted-by":"crossref","unstructured":"Janjua S, Pike KC, Carr R, Coles A, Fortescue R, Batavia M. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD). Cochrane Airways Group. ed. Cochrane Database Syst Rev. 2021;2021:CD013381.","DOI":"10.1002\/14651858.CD013381.pub2"},{"key":"3658_CR35","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.jaip.2023.03.053","volume":"11","author":"H De Keyser","year":"2023","unstructured":"De Keyser H, Vuong V, Kaye L, Anderson WC, Szefler S, Stempel DA. Is once versus twice daily dosing better for adherence in asthma and chronic obstructive pulmonary disease? J Allergy Clin Immunol Pract. 2023;11:2087\u201393. e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3658_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/pds.1552","volume":"17","author":"NS Breekveldt-Postma","year":"2008","unstructured":"Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JWJ, Herings RMC. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol Drug Saf. 2008;17:411\u201322.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3658_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1513\/AnnalsATS.201410-459OC","volume":"12","author":"AC Wu","year":"2015","unstructured":"Wu AC, Butler MG, Li L, Fung V, Kharbanda EO, Larkin EK, et al. Primary adherence to controller medications for asthma is poor. Ann Am Thorac Soc. 2015;12:161\u20136.","journal-title":"Ann Am Thorac Soc"},{"key":"3658_CR38","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jaip.2016.05.019","volume":"4","author":"B Vrijens","year":"2016","unstructured":"Vrijens B, Dima AL, Van Ganse E, van Boven JFM, Eakin MN, Foster JM, et al. What we mean when we talk about adherence in respiratory medicine. J Allergy Clin Immunol Pract. 2016;4:802\u201312.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03658-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03658-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:33:37Z","timestamp":1780965217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03658-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03658-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Kyushu University Observational Research Ethics Review Committee (approval number 22114-01) and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of the study and because the analysis was based on anonymous clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KT has received grants from Nippon Boehringer Ingelheim. IO has received grants and personal fees from Daiichi Sankyo, Chugai Pharma, Eli Lilly Japan, AstraZeneca, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, and Ono Pharmaceutical; grants from Bristol-Myers Squibb and MSD Oncology; and personal fees from Takeda Pharmaceutical and Novartis Pharma. All other authors report no relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}